SGDR
INDV icon

SPX Gestao de Recursos’s Indivior Pharmaceuticals INDV Stock Holding History

SPX Gestao de Recursos’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,000
Closed -$675K – 106
2025
Q3 		$675K Buy
+28,000
New +$586K 0.06% 115

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SPX Gestao de Recursos's INDV Position: Q4 2025 in Review

SPX Gestao de Recursos sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 28,000 shares — an estimated $675K sold.

SPX Gestao de Recursos first reported a position in INDV in Q3 2025 and held it in 1 quarter. The position peaked at $675K in Q3 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

  • SPX Gestao de Recursos reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • SPX Gestao de Recursos sold 28,000 Indivior Pharmaceuticals shares in Q4 2025, an estimated $675K.
  • SPX Gestao de Recursos first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • SPX Gestao de Recursos's Indivior Pharmaceuticals position peaked at $675K in Q3 2025.
  • 259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on SPX Gestao de Recursos's 13F filing for Q4 2025, filed 13 Feb 2026.